The Effects of Spironolactone on Calcineurin Inhibitor Induced Nephrotoxicity

PHASE4CompletedINTERVENTIONAL
Enrollment

188

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
Disorder Related to Renal Transplantation
Interventions
DRUG

Spironolactone

"One tablet per day (25 mg Spironolactone/placebo) for the first three months. Subsequently dosage is increased to two tablets per day (50 mg Spironolactone/placebo) for the rest of the study.~In case of hyperkaliemia (\>5,5 mmol/L) or intolerable side effects dosage will be reduced to one tablet per day (25 mg Spironolactone/placebo)."

DRUG

placebo

Trial Locations (1)

5000

Odense University Hospital, Odense C

All Listed Sponsors
collaborator

Fredericia Hosptial

OTHER

lead

Odense University Hospital

OTHER

NCT01602861 - The Effects of Spironolactone on Calcineurin Inhibitor Induced Nephrotoxicity | Biotech Hunter | Biotech Hunter